Mechanistically, VPA treatment was evidenced to result in significant inactivation of Akt and MAPK signalings via simultaneous down-regulation of EGFR, ErbB2, as well as ErbB3 in pancreatic cancer cells (Fig. 2). The gene discussed is AKT1; the disease is pancreatic neoplasm.